April 4, 2024

Siemens Healthcare Diagnostics, Inc. Kelly Scuderi   
Regulatory Affairs Professional   
511 Benedict Avenue   
Tarrytown, New York 10591

Re: K233050 Trade/Device Name: ADVIA Centaur $\textsuperscript { \textregistered }$ TSH3-Ultra II (TSH3ULII) Regulation Number: 21 CFR 862.1690 Regulation Name: Thyroid Stimulating Hormone Test System Regulatory Class: Class II Product Code: JLW Dated: March 1, 2024 Received: March 1, 2024

Dear Kelly Scuderi:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safetyreporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical  
devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn   
(https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

# Paula V. Caposino -S

Paula Caposino, Ph.D.   
Acting Deputy Director   
Division of Chemistry and Toxicology Devices OHT7: Office of In Vitro Diagnostics   
Office of Product Evaluation and Quality   
Center for Devices and Radiological Health

Enclosure

510(k) Number (if known) K233050

Device Name ADVIA Centau $\textsuperscript { \textregistered }$ TSH3-Ultra II (TSH3ULII)

This section applies only to requirements of the Paperwork Reduction Act of 1995.

# \*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

“An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number.”

# 510(k) Summary

# 510(k) Summary of Safety and Effectiveness

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

The assigned 510(k) number is: K233050

# 1. Applicant

Siemens Healthcare Diagnostics, Inc. 511 Benedict Avenue Tarrytown, NY 10591 USA

Contact: Kelly Scuderi   
Title: Regulatory Affairs Professional   
E-mail: kelly.scuderi@siemens-healthineers.com   
Phone: 781-856-6516

Date of Preparation: September 25, 2023

# 2. Device

# Regulatory Information

<table><tr><td rowspan=1 colspan=1>Device Name:</td><td rowspan=1 colspan=1>ADVIA Centaur® TSH3-Ultra II (TSH3ULII)</td></tr><tr><td rowspan=1 colspan=1>Classification Name:</td><td rowspan=1 colspan=1>Thyroid stimulating hormone test system</td></tr><tr><td rowspan=1 colspan=1>Regulation Number:</td><td rowspan=1 colspan=1>21 CFR 862.1690</td></tr><tr><td rowspan=1 colspan=1>Classification:</td><td rowspan=1 colspan=1>Class II</td></tr><tr><td rowspan=1 colspan=1>Product Code:</td><td rowspan=1 colspan=1>JLW</td></tr><tr><td rowspan=1 colspan=1>Review Panel:</td><td rowspan=1 colspan=1>Clinical Chemistry</td></tr></table>

# 3. Predicate Device

The predicate device, ADVIA Centau $\textsuperscript { \textregistered }$ TSH3-Ultra manufactured by Siemens Healthcare Diagnostics, Inc, Tarrytown, NY USA, was cleared by the FDA under K083844 and K150403.

# 4. Device Description

This assay is a third-generation assay that employs anti-FITC monoclonal antibody covalently bound to paramagnetic particles, an FITC-labeled anti-TSH capture mouse monoclonal antibody, and a tracer consisting of a proprietary acridinium ester and an anti‑TSH mouse monoclonal antibody conjugated to bovine serum albumin (BSA) for chemiluminescent detection.

# 5. Intended Use

The ADVIA Centaur $\textsuperscript { \textregistered }$ TSH3‑Ultra II (TSH3ULII) assay is for in vitro diagnostic use in the quantitative determination of thyroid-stimulating hormone (TSH, thyrotropin) in human serum

and plasma (EDTA and lithium heparin) using the ADVIA Centaur $\textsuperscript { \textregistered }$ XP system. Measurements of thyroid stimulating hormone produced by the anterior pituitary are used in the diagnosis of thyroid or pituitary disorders.

# 6. Indications for Use

Same as Intended use.

# 7. Comparison of Technological Characteristics with the Predicate Device

The following table provides a comparison between the predicate and candidate device.

<table><tr><td rowspan=1 colspan=3>tweer tre pr</td></tr><tr><td rowspan=1 colspan=1>Attribute</td><td rowspan=1 colspan=1>Candidate Device:ADVIA Centaur TSH3-Ultra II(TSH3ULII)</td><td rowspan=1 colspan=1>Predicate Device:ADVIA Centaur TSH3-UltraK083844/K150403</td></tr><tr><td rowspan=1 colspan=1>Intended Use / Indications forUse</td><td rowspan=1 colspan=1>The ADVIA Centaur TSH3-Ultra II(TSH3ULIl) assay is for in vitro diagnosticuse in the quantitative determination ofthyroid-stimulating hormone (TSH,thyrotropin) in human serum and plasma(EDTA and lithium heparin) using theADVIA Centaur® XP system.Measurements of thyroid stimulatinghormone produced by the anteriorpituitary are used in the diagnosis ofthyroid or pituitary disorders.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>TSH</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Automated</td><td rowspan=1 colspan=1>Automated assay</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Measurement</td><td rowspan=1 colspan=1>Quantitative</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Human serum and plasma</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Detection Limit</td><td rowspan=1 colspan=1>LoQ: 0.010 μlU/mL (mlU/L)</td><td rowspan=1 colspan=1>LoQ: 0.008 μlU/mL (mIU/L)</td></tr><tr><td rowspan=1 colspan=1>Assay Range</td><td rowspan=1 colspan=1>0.010-150.000 µlU/mL (mlU/L)</td><td rowspan=1 colspan=1>0.008—150 µlU/mL (mIU/L)</td></tr><tr><td rowspan=1 colspan=1>Operating Principle</td><td rowspan=1 colspan=1>Immunologic sandwich</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Technology</td><td rowspan=1 colspan=1>Direct chemiluminescent</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Lite Reagent Antibody</td><td rowspan=1 colspan=1>Mouse monoclonal anti-TSH antibodyBSA conjugate labeled with acridiniumester</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Solid Phase Antibody</td><td rowspan=1 colspan=1>FITC-labeled mouse monoclonal anti-TSHantibody and mouse monoclonal anti-fluorescein antibody linked toparamagnetic particles</td><td rowspan=1 colspan=1>Mouse monoclonal anti-fluoresceinantibody linked toparamagnetic particles</td></tr><tr><td rowspan=1 colspan=1>Ancillary Antibody</td><td rowspan=1 colspan=1>FITC conjugated to mouse monoclonalanti-TSH antibody</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Volume</td><td rowspan=1 colspan=1>100 μL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibrator</td><td rowspan=1 colspan=1>After reconstitution, TSH (human); buffer;equine serum; sodium azide (&lt; 0.1%);stabilizers; preservatives</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Number of Calibrators</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibrators Packaging</td><td rowspan=1 colspan=1>Provided with reagent kit</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Use of Controls</td><td rowspan=1 colspan=1>Yes (recommended)</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Traceability</td><td rowspan=1 colspan=1>Traceable to the World HealthOrganization (WHO) 3rd InternationalReference Preparation for human TSH(IRP 81/565).</td><td rowspan=1 colspan=1>Same</td></tr></table>

# 8. Performance Characteristics Data

Detection Capability

Limit of Blank (LoB) 0.005 μIU/mL (mIU/L) Limit of Detection (LoD) 0.008 μIU/mL (mIU/L) Limit of Quantitation (LoQ) 0.010 μIU/mL (mIU/L)

Detection capability was determined in accordance with CLSI Document EP17‑A2.

The LoB corresponds to the highest measurement result likely to be observed for a blank sample with a probability of $9 5 \%$ . The LoD corresponds to the lowest analyte concentration that can be detected with a probability of $9 5 \%$ . The LoQ corresponds to the lowest analyte concentration at which the within laboratory CV is $\leq 2 0 \%$ .

# Precision

Precision was determined in accordance with CLSI Document EP05‑A3. Samples were assayed in replicates of 2 with 2 runs per day using a 20-day protocol.

The following results are representative of the performance of the assay:   

<table><tr><td colspan="3"></td><td colspan="2">Repeatability</td><td colspan="2">Within-Laboratory Precision</td></tr><tr><td>Sample</td><td>Na</td><td>Mean μIU/mL (mlU/L)</td><td>SDb μIU/mL (mlU/L)</td><td>CVc (%)</td><td>SD μlU/mL (mIU/L)</td><td>CV (%)</td></tr><tr><td>Serum A</td><td>80</td><td>0.088</td><td>0.0022</td><td>2.5</td><td>0.0032</td><td>3.6</td></tr><tr><td>Serum B</td><td>80</td><td>0.196</td><td>0.0035</td><td>1.8</td><td>0.0062</td><td>3.1</td></tr><tr><td>Serum C</td><td>80</td><td>0.507</td><td>0.0086</td><td>1.7</td><td>0.0134</td><td>2.6</td></tr><tr><td>Serum D</td><td>80</td><td>4.752</td><td>0.1083</td><td>2.3</td><td>0.1293</td><td>2.7</td></tr><tr><td>Serum E</td><td>80</td><td>46.749</td><td>1.1297</td><td>2.4</td><td>1.8749</td><td>4.0</td></tr><tr><td>Serum F</td><td>80</td><td>97.929</td><td>2.1282</td><td>2.2</td><td>3.4288</td><td>3.5</td></tr><tr><td>Plasma, lithium heparin A</td><td>80</td><td>0.099</td><td>0.0014</td><td>1.4</td><td>0.0029</td><td>2.9</td></tr><tr><td>Plasma, lithium heparin B</td><td>80</td><td>0.520</td><td>0.0089</td><td>1.7</td><td>0.0175</td><td>3.4</td></tr><tr><td>Plasma, lithium heparin C</td><td>80</td><td>4.908</td><td>0.0763</td><td>1.6</td><td>0.1139</td><td>2.3</td></tr><tr><td>Plasma, lithium heparin D</td><td>80</td><td>53.262</td><td>0.7579</td><td>1.4</td><td>1.5032</td><td>2.8</td></tr><tr><td>Sample</td><td>N^a$</td><td>Mean μlU/mL (mlU/L)</td><td>SDb μlU/mL (mlU/L)</td><td>CVc (%)</td><td>SD μIU/mL (mlU/L)</td><td>CV (%)</td></tr><tr><td>Plasma, lithium heparin E</td><td>80</td><td>91.993</td><td>3.2754</td><td>3.6</td><td>5.7348</td><td>6.2</td></tr><tr><td>Control 1</td><td>80</td><td>0.104</td><td>0.0021</td><td>2.1</td><td>0.0035</td><td>3.4</td></tr><tr><td>Control 2</td><td>80</td><td>0.516</td><td>0.0087</td><td>1.7</td><td>0.0203</td><td>3.9</td></tr><tr><td>Control 3</td><td>80</td><td>4.778</td><td>0.0811</td><td>1.7</td><td>0.1316</td><td>2.8</td></tr><tr><td>Control 4</td><td>80</td><td>47.494</td><td>0.6508</td><td>1.4</td><td>1.7552</td><td>3.7</td></tr><tr><td>Control 5</td><td>80</td><td>99.366</td><td>1.5194</td><td>1.5</td><td>2.9443</td><td>3.0</td></tr></table>

a Number of measurements. b Standard deviation. cCoefficient of variation.

The assay was designed to have the following precision when using a 20-day protocol in accordance with CLSI Document EP05‑A3:   

<table><tr><td></td><td colspan="2">Precision</td></tr><tr><td>Concentration Interval</td><td>Repeatability (Within-Run)</td><td>Within-Laboratory (Total Precision)</td></tr><tr><td>0.020-0.299 µlU/mL (mIU/L)</td><td>≤ 12% CV</td><td>≤ 16% CV</td></tr><tr><td>≥ 0.300-90.000 μIU/mL (mIU/L)</td><td>≤ 6% CV</td><td>≤ 8% CV</td></tr><tr><td>&gt; 90.000 μIU/mL (mIU/L)</td><td>≤ 7% CV</td><td>≤ 10% CV</td></tr></table>

# Reproducibility

Reproducibility was determined in accordance with CLSI Document EP05‑A3. Testing was performed using 3 instruments and 3 reagent lots. Samples were assayed in replicates of 5 with 1 run per day using a 5-day protocol (225 measurements per sample).

The following results are representative of the performance of the assay:

<table><tr><td></td><td>Mean</td><td colspan="2">Repeatability</td><td colspan="2">Between Day</td><td colspan="2">Between Lot</td><td colspan="2">Between Instrument</td><td colspan="2">Reproducibility</td></tr><tr><td>Sample</td><td>μlU/mL (mlU/L)</td><td>SD° μlU/mL (mlU/L)</td><td>CVb (%)</td><td>SD μIU/mL (mIU/L)</td><td>CV (%)</td><td>SD μlU/mL (mlU/L)</td><td>CV (%)</td><td>SD μlU/mL (mlU/L)</td><td>CV (%)</td><td>SD μlU/mL (mlU/L)</td><td>CV (%)</td></tr><tr><td>Serum A</td><td>0.090</td><td>0.002</td><td>1.99</td><td>0.001</td><td>1.41</td><td>0.002</td><td>1.80</td><td>0.001</td><td>0.67</td><td>0.003</td><td>3.11</td></tr><tr><td>Serum B</td><td>0.178</td><td>0.008</td><td>4.73</td><td>0.002</td><td>0.91</td><td>0.001</td><td>0.70</td><td>0.000</td><td>0.22</td><td>0.009</td><td>4.87</td></tr><tr><td>Serum C</td><td>0.474</td><td>0.007</td><td>1.47</td><td>0.005</td><td>0.95</td><td>0.006</td><td>1.34</td><td>0.000</td><td>0.00</td><td>0.010</td><td>2.21</td></tr><tr><td>Serum D</td><td>4.684</td><td>0.075</td><td>1.61</td><td>0.061</td><td>1.29</td><td>0.062</td><td>1.32</td><td>0.015</td><td>0.32</td><td>0.116</td><td>2.47</td></tr><tr><td>Serum E</td><td>56.562</td><td>0.953</td><td>1.68</td><td>0.539</td><td>0.95</td><td>0.337</td><td>0.60</td><td>0.649</td><td>1.15</td><td>1.316</td><td>2.33</td></tr><tr><td>Serum F</td><td>99.522</td><td>2.118</td><td>2.13</td><td>1.101</td><td>1.11</td><td>2.448</td><td>2.46</td><td>2.254</td><td>2.26</td><td>4.095</td><td>4.12</td></tr><tr><td>Plasma A</td><td>0.093</td><td>0.002</td><td>2.17</td><td>0.001</td><td>1.42</td><td>0.001</td><td>1.50</td><td>0.000</td><td>0.44</td><td>0.003</td><td>3.03</td></tr><tr><td>Plasma B</td><td>0.436</td><td>0.011</td><td>2.63</td><td>0.007</td><td>1.72</td><td>0.005</td><td>1.11</td><td>0.003</td><td>0.71</td><td>0.015</td><td>3.40</td></tr><tr><td>Plasma C</td><td>4.490</td><td>0.115</td><td>2.55</td><td>0.103</td><td>2.30</td><td>0.043</td><td>0.96</td><td>0.036</td><td>0.80</td><td>0.164</td><td>3.66</td></tr><tr><td>Plasma D</td><td>49.569</td><td>1.129</td><td>2.28</td><td>1.275</td><td>2.57</td><td>0.305</td><td>0.62</td><td>1.212</td><td>2.44</td><td>2.112</td><td>4.26</td></tr><tr><td>Plasma E</td><td>102.084</td><td>1.879</td><td>1.84</td><td>1.202</td><td>1.18</td><td>0.502</td><td>0.49</td><td>2.239</td><td>2.19</td><td>3.200</td><td>3.13</td></tr><tr><td>Control 1</td><td>0.103</td><td>0.002</td><td>2.03</td><td>0.001</td><td>0.75</td><td>0.002</td><td>1.79</td><td>0.001</td><td>1.01</td><td>0.003</td><td>2.98</td></tr><tr><td>Control 2</td><td>0.516</td><td>0.007</td><td>1.38</td><td>0.004</td><td>0.82</td><td>0.007</td><td>1.36</td><td>0.000</td><td>0.00</td><td>0.011</td><td>2.10</td></tr><tr><td>Control 3</td><td>4.716</td><td>0.069</td><td>1.47</td><td>0.036</td><td>0.76</td><td>0.065</td><td>1.37</td><td>0.000</td><td>0.00</td><td>0.101</td><td>2.15</td></tr><tr><td>Control 4</td><td>47.003</td><td>0.712</td><td>1.52</td><td>0.572</td><td>1.22</td><td>0.272</td><td>0.58</td><td>0.521</td><td>1.11</td><td>1.086</td><td>2.31</td></tr><tr><td>Control 5</td><td>99.051</td><td>1.790</td><td>1.81</td><td>2.111</td><td>2.13</td><td>0.000</td><td>0.00</td><td>1.930</td><td>1.95</td><td>3.374</td><td>3.41</td></tr></table>

a Standard deviation. b Coefficient of variation.

The assay was designed to have the following reproducibility when using a 5-day protocol in accordance with CLSI Document EP05‑A3:   

<table><tr><td>Concentration Interval</td><td>Reproducibility</td></tr><tr><td>0.0200.299 µlU/mL (mlU/L)</td><td>≤ 18.5% CV</td></tr><tr><td>≥ 0.300-90.000 μIU/mL (mIU/L)</td><td>≤ 10.5% CV</td></tr><tr><td>&gt; 90.000 μIU/mL (mIU/L)</td><td>≤ 12.5% CV</td></tr></table>

# Assay Comparison

Assay comparison was determined with the Passing-Bablok regression model in accordance with CLSI Document EP09c‑ed3.

Agreement of the assays may vary depending on the study design, comparative assay, and population tested.

<table><tr><td></td><td>Sample Comparative Assay ()</td><td>Regression Equation Sample Interval Na rb</td><td></td><td></td><td></td></tr><tr><td>Serum </td><td>ADVIA Centaur TSH3-ULassy u y= 0.97x - 0.007 μIU/mL0.01247.3 μIU/mL 0 the ADVIA Centaur XP system</td><td></td><td></td><td></td><td></td></tr></table>

a Number of samples tested. b Correlation coefficient.

The assay is designed to have a correlation coefficient of $\ge 0 . 9 5$ and a slope of $1 . 0 \pm 0 . 1$ .

# Specimen Equivalency

Specimen equivalency was determined with the Passing-Bablok regression model using the ADVIA Centaur XP system in accordance with CLSI Document EP09c‑ed3.

Agreement of the specimen types may vary depending on the study design and population tested.

<table><tr><td>Tube (y) vs. Serum (x)</td><td>Regression Equation</td><td>Sample Interval</td><td>Na</td><td>rb</td></tr><tr><td>Plasma, EDTA</td><td>y = 0.99x - 0.019 µlU/mL</td><td>0.050-147.805 µlU/mL</td><td>52</td><td>0.999</td></tr><tr><td>Plasma, lithium heparin</td><td>y = 1.01x - 0.034 µlU/mL</td><td>0.115-135.881 µlU/mL</td><td>57</td><td>0.990</td></tr></table>

a Number of samples tested. b Correlation coefficient.

The assay is designed to have a correlation coefficient of $\ge 0 . 9 5$ and a slope of 0.95–1.05.

# Interferences

Hemolysis, Icterus, Lipemia (HIL):

Interference testing was performed using the ADVIA Centaur XP system in accordance with CLSI Document EP07‑ed3.

The following substances do not interfere with the assay when present in serum at the concentrations indicated. Bias due to these substances does not exceed $10 \%$ at a TSH concentration of approximately 0.900 μIU/mL (mIU/L) and 8.000 μIU/mL (mIU/L).

<table><tr><td>Substance</td><td>Substance Test Concentration</td></tr><tr><td>Hemoglobin</td><td>500 mg/dL (5.00 g/L)</td></tr><tr><td>Bilirubin, conjugated</td><td>40 mg/dL (474 µmol/L)</td></tr><tr><td>Bilirubin, unconjugated</td><td>40 mg/dL (684 µmol/L)</td></tr><tr><td>Lipemia (Intralipid)</td><td>1000 mg/dL (11.3 mmol/L)</td></tr></table>

Other Substances:

Interference testing was performed using the ADVIA Centaur XP system in accordance with CLSI Document EP07‑ed3.

The following substances do not interfere with the assay when present in serum at the concentrations indicated. Bias due to these substances does not exceed $10 \%$ at TSH concentrations of approximately $0 . 9 0 0 \mu \mu \mu / \mu \mathrm { { m L } }$ (mIU/L) and 8.000 μIU/mL (mIU/L).

<table><tr><td>Substance</td><td>Substance Test Concentration</td><td>Substance</td><td>Substance Test Concentration</td></tr><tr><td>Acetaminophen</td><td>15.6 mg/dL (1033 µmol/L)</td><td>Liothyronine</td><td>0.0075 mg/dL (0.116 µmol/L)</td></tr><tr><td>Acetylsalicylic acid 3.0 mg/dL (167 μmol/L)</td><td></td><td>Methimazole</td><td>8.0 mg/dL (701 µmol/L)</td></tr><tr><td>Ampicillin</td><td>7.5 mg/dL (215 µmol/L)</td><td>Methyldopa</td><td>2.25 mg/dL (107 µmol/L)</td></tr><tr><td>Ascorbic Acid</td><td>5.25 mg/dL (298 μmol/L)</td><td>Metronidazole</td><td>12.3 mg/dL (719 µmol/L)</td></tr><tr><td>Biotin</td><td>0.35 mg/dL (14.3 µmol/L)</td><td>N-Acetylcysteine</td><td>15.0 mg/dL (920 µmol/L)</td></tr><tr><td>Carbimazole</td><td>3.0 mg/dL (161 µmol/L)</td><td>Octreotide</td><td>0.03 mg/dL (0.294 µmol/L)</td></tr><tr><td>Cefoxitin</td><td>495 mg/dL (11583 µmol/L)</td><td>Phenylbutazone</td><td>32.1 mg/dL (1040 µmol/L)</td></tr><tr><td>Cholesterol</td><td>400 mg/dL (10.3 mmol/L)</td><td>Propranolol</td><td>24 mg/dL (926 µmol/L)</td></tr><tr><td>Cyclosporine</td><td>0.18 mg/dL (1.50 µmol/L)</td><td>Propylthiouracil</td><td>30 mg/dL (1762 µmol/L)</td></tr><tr><td>Doxycycline</td><td>1.8 mg/dL (40.5 µmol/L)</td><td>Rheumatoid Factor 1500 IU/mL</td><td></td></tr><tr><td>Heparin</td><td>7500 U/dL</td><td>Rifampicin</td><td>4.8 mg/dL (58.6 µmol/L)</td></tr><tr><td>Ibuprofen</td><td>21.9 mg/dL (1062 µmol/L)</td><td>Theophylline</td><td>6.0 mg/dL (333 μmol/L)</td></tr><tr><td>Levodopa</td><td>0.75 mg/dL (38.0 µmol/L)</td><td>Total Protein</td><td>15 g/dL (150 g/L)</td></tr><tr><td>Levothyroxine</td><td>0.0429 mg/dL (0.552 µmol/L)</td><td></td><td></td></tr></table>

# Cross-Reactivity

Cross-reactivity was determined using the ADVIA Centaur XP system in accordance with CLSI Document EP07‑ed3.21 Cross-reactivity of samples spiked with various substances does not exceed $5 \%$ at TSH concentrations of approximately 0.400 μIU/mL (mIU/L), 5.00 μIU/mL (mIU/L), $1 7 . 0 0 \mu \mu \mu / \mu \mathrm { { m L } }$ (mIU/L), and 90.00 μIU/mL (mIU/L).

<table><tr><td>Substance</td><td>Substance Test Concentration</td></tr><tr><td>hCG</td><td>200000 mlU/mL</td></tr><tr><td>FSH</td><td>1500 mlU/mL</td></tr><tr><td>LH</td><td>600 mlU/mL</td></tr></table>

# Linearity

Linearity testing was performed in accordance with CLSI Document EP06-ed2.

The assay is linear for the measuring interval of 0.010–150.000 μIU/mL (mIU/L).

# High-Dose Hook Effect

High TSH concentrations can cause a paradoxical decrease in the RLUs (high-dose hook effect). In this assay, patient samples with TSH concentrations above the measuring interval and as high as $3 0 0 0 \mu \mu / \mu \mu$ will report $>$ 150 μIU/mL (mIU/L).

# Standardization

The assay standardization is traceable to the World Health Organization (WHO) 3rd International Reference Preparation for human TSH (IRP 81/565).

Assigned values for calibrators are traceable to this standardization.

# 9. Conclusion

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.